Intratumour heterogeneity (ITH) is a hallmark of cancer that drives tumour evolution and
disease progression. Technological and computational advances have enabled us to …

The population of cells that make up a cancer are manifestly heterogeneous at the genetic,
epigenetic, and phenotypic levels. In this mini-review, we summarise the extent of intra …

The observation and analysis of intra-tumour heterogeneity (ITH), particularly in genomic
studies, has advanced our understanding of the evolutionary forces that shape cancer …

Intratumor heterogeneity represents a major obstacle to effective cancer treatment and
personalized medicine. However, investigators are now elucidating intratumor heterogeneity …

Simple Summary Most malignant tumours are highly heterogeneous at molecular and
phenotypic levels. Tumour variability poses challenges for the management of patients, as it …

Recent technologic advances have permitted higher resolution and more rapid analysis of
individual cancer genomes at the single-nucleotide level. Such advances have shown …

As tumors accumulate genetic alterations, an evolutionary process occurs in which
genetically distinct subclonal populations of cells co-exist, resulting in intratumor genetic …

In this review, we highlight the role of intratumoral heterogeneity, focusing on the clinical and
biological ramifications this phenomenon poses. Intratumoral heterogeneity arises through …

Cells within tumours have diverse genomes and epigenomes and interact differentially with
their surrounding microenvironment generating intratumour heterogeneity, which has critical …

Cancer patients die primarily due to disease recurrence after transient treatment responses.
The emergence of therapy‐resistant escape variants is fuelled by intra‐tumour …